These 3 Marijuana Stocks Have Minted Our Readers Gains Up to 990% – and Counting

Marijuana stocks are in high demand now that over 29 states have legalized marijuana in some form. As more states adopt legalization, opportunities for marijuana entrepreneurs – and pot stock investors – abound.

2016 North American sales for legal marijuana topped $6.7 billion; by 2020, analysts expect sales to climb to $21.8 billion.

That's a 225% increase in sales in just four years.

But in order to take advantage of the trend and be a successful pot stock investor, you need to be able to separate the frontrunners from the duds.

That's why we're showing you how to easily find the right pot stocks to buy (and how to buy them) for the biggest profit potential in 2017.

You see, now is a better time than ever.

Along with many other equities, cannabis and related stocks have enjoyed triple-digit gains since the post-election "Trump Bump."

However, the market has steadied from its post-election rally, creating attractive entry points.

Here's a list of three marijuana stocks that have made our readers rich, plus the latest pot stock play from our renowned marijuana expert, Michael A. Robinson…

Best Marijuana Stocks No. 3: Lexaria Bioscience Corp. (OTCMKTS: LXRP)

Lexaria Bioscience Corp. provides edibles infused with hemp oil to all 50 states. In the long term, Lexaria plans to launch a hemp oil-infused protein bar as well as teas, coffees, and related goods.

We first told you about Lexaria Bioscience back in November 2016, when it was trading at just $0.24 per share.

Now, the small cannabis company is trading at $0.36 per share – a 50% increase.

And it's poised to keep growing…

"[Lexaria's] technology has proven to be a potential game changer in the cannabinoid-based pharmaceuticals market, an industry that's on course to grow to $50 billion by 2029, per data aggregated by Statista," according to Biotech Investing News on Aug. 18.

Best Marijuana Stocks No. 2: Insys Therapeutics Inc. (Nasdaq GM: INSY)

Insys Therapeutics stock gave Money Morning readers nearly 26% gains in just 12 trading sessions after we recommended buying the stock on May 14.

In fact, we told you about this company before the U.S. Food and Drug Administration (FDA) even gave the company final approval for its new drug on May 24.

And that approval is just the beginning of big profits for our readers…

Syndros – the company's blockbuster new drug – is positioned to be a leading player in a very large market.

Special Report: Cannabis Is the Gold Rush of the 21st Century – 30 Stocks to Invest in Now. Read more…

Syndros is a cannabinoid-derived drug that helps fight nausea and pain.

The National Cancer Institute reports that 15 million U.S. patients were treated for cancer in 2014, and 80% of those patients experienced nausea and vomiting from chemotherapy.

And in 2015, Transparency Market Research reported that the pain market was worth over $60 billion. By 2024, it is expected to hit $83 billion. That's more than a 33% increase.

That means Insys is well-positioned to capitalize on this $83 billion market with its latest drug.

This next pot stock is our biggest winner to date, with a 990% return since we recommended it to readers four years ago. Not only that, it's the absolute best pot stock to buy for risk-averse investors…